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observational study of cystic fibrosis
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Judy L. Jensen1, Ruth Keogh10, Carol M. Kopecky11, Noah Lechtzin12, Yanping Li1, Jerimiah Lysinger13,
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Abstract
Background: Biomarkers of inflammation predictive of cystic fibrosis (CF) disease outcomes would increase the
power of clinical trials and contribute to better personalization of clinical assessments. A representative patient
cohort would improve searching for believable, generalizable, reproducible and accurate biomarkers.
Methods: We recruited patients from Mountain West CF Consortium (MWCFC) care centers for prospective
observational study of sputum biomarkers of inflammation. After informed consent, centers enrolled randomly
selected patients with CF who were clinically stable sputum producers, 12 years of age and older, without previous
organ transplantation.
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Results: From December 8, 2014 through January 16, 2016, we enrolled 114 patients (53 male) with CF with
continuing data collection. Baseline characteristics included mean age 27 years (SD = 12), 80% predicted forced
expiratory volume in 1 s (SD = 23%), 1.0 prior year pulmonary exacerbations (SD = 1.2), home elevation 328 m
(SD = 112) above sea level. Compared with other patients in the US CF Foundation Patient Registry (CFFPR) in 2014,
MWCFC patients had similar distribution of sex, age, lung function, weight and rates of exacerbations, diabetes,
pancreatic insufficiency, CF-related arthropathy and airway infections including methicillin-sensitive or -resistant
Staphylococcus aureus, Pseudomonas aeruginosa, Burkholderia cepacia complex, fungal and non-tuberculous
Mycobacteria infections. They received CF-specific treatments at similar frequencies.
Conclusions: Randomly-selected, sputum-producing patients within the MWCFC represent sputum-producing
patients in the CFFPR. They have similar characteristics, lung function and frequencies of pulmonary exacerbations,
microbial infections and use of CF-specific treatments. These findings will plausibly make future interpretations of
quantitative measurements of inflammatory biomarkers generalizable to sputum-producing patients in the CFFPR.
Keywords: Cystic fibrosis, Randomized observational trial, Study design, Sputum inflammation, HMGB-1, Neutrophil
elastase, Calprotectin, Cystic Fibrosis Foundation patient registry
Background
Neutrophil-predominant, intense airway inflammation
associated with chronic airway infections drives CF dis-
ease. Multiple molecules [1–4] describe and mediate air-
way inflammation in CF. These biochemical markers of
airway inflammation may mark disease progression and
potentially provide surrogate markers of survival or
intermediate outcomes that could improve the power of
clinical trials to demonstrate efficacy of novel treatments
[2, 3, 5–8]. Lung function, pulmonary exacerbations and
weight are the best clinical predictors of survival [9, 10]
and are the key end-points for multiple trials with high
impact on CF treatment [11–17]. However, the insensi-
tivity of these clinical markers requires large trial enroll-
ments and prolonged observation to ascertain effects
[11, 13, 15, 18]. Understanding relationships between these
clinical features of disease and the laboratory measurements
of biomarkers of inflammation will improve our knowledge
of pathophysiology and enable better understanding of the
impacts of current and investigational treatments.
Most evaluated inflammatory signals are increased in
CF airways relative to normal airways [3, 19–21]. Three
potentially useful biomarkers are associated with disease
progression. High mobility group box-1 protein
(HMGB-1), a highly conserved protein [22, 23], is associ-
ated with pulmonary exacerbations [24]. Sputum con-
centration correlates with concurrent lung function and
number of prior-year exacerbations [25]. HMGB-1 spu-
tum concentration predicts time to next exacerbation,
number of subsequent pulmonary exacerbations and
time to death or lung transplantation in CF. [25] Calpro-
tectin, a proinflammatory molecule found abundantly in
CF sputum, decreases with antibiotic treatment; high
levels are associated with more rapid recurrence of a
pulmonary exacerbation [26, 27]. Neutrophil elastase ac-
tivity (NE) appears in airway secretions in CF [28],
induces interleukin-(IL)-8 production [29], and predicts
accelerated lung function loss in children with CF [5].
Finally, granulocyte macrophage colony stimulating
factor (GMCSF) is another potentially useful biomarker.
Its concentration in sputum at the beginning of
hospitalization for a pulmonary exacerbation was
strongly associated with the acute decrease in forced ex-
piratory volume in 1 s (FEV1) normalized to percent pre-
dicted FEV1 for age, height, sex, race and ethnicity
(FEV1%) [25, 30]. GMCSF may thus be an objective
measurement of severity of an exacerbation.
However, all studies of these four potential biomarkers
in CF were performed in single centers among patients re-
cruited in ways subject to observer biases [5, 24, 25, 27].
Comparisons of predictive ability for future clinically rele-
vant events between HMGB-1, calprotectin and neutro-
phil elastase cannot be done with existing data. We
designed and implemented an observational study in
the Mountain West CF Consortium (MWCFC) to
allow direct comparison of the potential biomarkers
and reduce biases. Because this study could facilitate
the assessment of other clinically relevant conditions
in CF and their relationship to inflammation with
relatively small incremental costs, we included add-
itional biomarkers and data collections in our study
design to evaluate combinations of the primary mole-
cules with each other and with other inflammatory
markers to understand both our primary clinical
event, pulmonary exacerbations, and additional sec-
ondary clinical conditions of high importance.
We report here the nature and implementation of our
study design centered on randomized patient selection.
This methodology strives to minimize observer bias in re-
cruitment to maximize believability and generalizability of
analysis [31, 32]. To demonstrate success, we compared
cohort characteristics with patients in the CF Foundation
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Patient Registry (CFFPR) [33] in 2014 who would have ful-
filled inclusion and exclusion criteria.
Methods
Study setting
Nine CF Care Centers accredited by the US CF Founda-
tion and located in the Mountain West Region partici-
pated in this trial. The Mountain West Region includes
(from North to South and West to East) Idaho,
Montana, Wyoming, Nevada, Utah, Colorado, Arizona,
and New Mexico. MWCFC centers provide care to
about 10% of the patients with CF [34] who live in ap-
proximately 25% of the total land area of all 50 of the
United States [35].
Pre-study preparations
Prior to the general study planning meeting, the initial
investigators (TGL, FRA, JLJ, RK, DRC) held multiple
discussions to develop core statistical and logistical study
plans. At the meeting, RK and DRC taught on core de-
sign issues (Additional files 1, 2 and 3, Video: Principles
of Study Design: A Conversation Between David Cox
and Ruth Keogh and Additional file 4: Transcript of
Video) to improve the understanding of all investigators
for study procedures. Two non-MWCFC collaborators
provided guidance on additional important design ele-
ments (NL, ALQ), and three clinical investigators served
as an external advisory committee (JPC, JSE, KNO) to
review and modify procedures and provide oversight.
All personnel were trained at the University of Utah in
study background, goals, inclusion and exclusion criteria,
good clinical practice, patient safety and study procedures,
data entry and records security. Research coordinators
and laboratory personnel were trained individually at the
University of Utah on sputum processing. The overall
principal investigator (PI, TGL) and research manager
(JLJ) performed on-site study initiation and training of in-
vestigators, study coordinators and laboratory technicians.
Additional training was provided on-site or in Utah as
requested. Training records were archived at each site and
at the University of Utah.
Study endpoints
The primary event for this observational trial is first pul-
monary exacerbation following enrollment. The investi-
gators at the general study planning meeting discussed
previously published definitions for pulmonary exacerba-
tions. Many clinical trials include a decision to start par-
enteral antibiotics in the criteria in order to facilitate
retrospective identification of exacerbations [11]. After
careful consideration, we decided to use the definition
used in our original single center study (Table 1) [25] for
several reasons: (A) we intended our primary event to be
determined in a prospective manner, (B) a definition
including use of parenteral antibiotics could have intro-
duced bias in determination of a pulmonary exacerba-
tion at the point of care, (C) the requirement for
antibiotics might have been viewed as requiring an inter-
vention despite ours being an observational study, and
(D) a central goal was replication of results from the ori-
ginal single center study [25].
We considered using a scoring system to diagnose a
pulmonary exacerbation [36] but felt that the additional
complexity might reduce reporting of events especially
for patients evaluated by clinicians not participating dir-
ectly in the study. Because patients can be unstable but
not quite reach the severity of disease described by our
definition (Table 1), we defined a category of “mild ex-
acerbation” to reduce the likelihood of arbitrary mis-
classification and to allow future investigation of this
poorly defined clinical state.
The investigators and the external advisory commit-
tee reached unanimous consensus agreement with the
definitions prior to enrollment of patients. These defi-
nitions were included in the application for investiga-
tional review board (IRB) or equivalent ethical
oversight organization at all participating centers in
the MWCFC.
Table 1 Symptoms and signs of a pulmonary exacerbation of CFa
Symptoms Signs
increased sputum, cough, dyspnea 10% drop in FEV1 or forced vital capacity
chest pain or tightness Temperature > 38.4 °C
hemoptysis Witnessed hemoptysis greater than 100 ml per episode
fever SaO2 < 90% or PaO2 < 60mmHg despite usual oxygen
chills For adolescents a drop in SaO2 of 5% (for example, 97 to 92%)
arthralgias Increased supplemental oxygen requirements
fatigue Unplanned weight loss ≥5% of baseline body weight over 3 months
Other Considerations
Respiratory arrest or failure requiring mechanical ventilation regardless of other criteria
At site PI discretion for borderline cases or for cases with serious findings not included here
aA pulmonary exacerbation is defined as the presence of one symptom and one objective finding
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Because there are multiple clinical questions for which
insufficient information exists to allow independent
studies, we discussed potential additional data collec-
tions and laboratory assessments. We incorporated add-
itional clinical annotations and sample analyses that
were judged feasible and that would have minimal po-
tential to introduce bias or alter enrollment in our pri-
mary study.
Enrollment
After obtaining IRB approvals, we reviewed center-specific
potential participant lists. Each center identified patients
with confirmed CF either (A) older than 18 years of age
able to provide informed consent and to expectorate spu-
tum or (B) older than 12 (but less than 18) years able to
provide assent and able to expectorate sputum or success-
fully undergo sputum induction as part of normal care,
with parents or guardians able to consent. We enrolled
patients after written informed consent only when judged
clinically stable by enrolling investigators. We excluded
patients unable or unwilling to provide sputum or who
had previously received organ transplantation, were on
immunosuppression beyond oral prednisone or on treat-
ment with immunologic-based biologic therapies. We ex-
cluded pregnant women, prisoners and other vulnerable
patients from enrollment but did not require withdrawal if
a patient became vulnerable because of the non-coercive
nature of continued participation in an observational
study. Patients, guardians or investigators could request
withdrawal at any time.
Power calculations
We sampled prior data and bootstrapped models to esti-
mate the number of patients required to detect associa-
tions for HMGB-1 concentrations, our primary biomarker
for study, with pulmonary exacerbations and survival out-
comes [25, 37]. We additionally calculated the number of
patients needed to study associations between GMCSF
concentration and acute drops in FEV1% at the beginning
of a pulmonary exacerbation [25] and NE with drops in
FEV1% among children [5] over two years of follow up
(Table 2). Based on these calculations, we planned a mini-
mum enrollment of at least 40 patients to explore the abil-
ity of our primary biomarker, HMGB-1, to predict our
primary event, time to first pulmonary exacerbation.
However, we hoped to enroll as many as 125 to a max-
imum of 175 patients, including both adults and children,
to enable a believable and financially feasible analysis (see
Additional files 1, 2, 3 and 4) of GMCSF as a reporter of
severity of a pulmonary exacerbation [25].
Randomized selection of patients
To minimize observer bias (Additional files 2 and 4)
[31, 32] and enroll a representative sample of patients
with CF, we assigned a randomly chosen letter of the
alphabet to each potentially eligible patient using one
adult and one pediatric block per MWCFC center.
Based on a prior recruitment rate of 53% [25], and
allowing for a 10% clinic no-show rate, we chose a
letter of the alphabet to assign to each adult and
pediatric center to serve as the threshold between
random inclusion or exclusion from enrollment. We
recruited eligible patients attending clinic who had
been assigned personal random letters earlier in the
alphabet than the threshold letter for the center. The
method eliminated the need for research coordinators
to visit clinic for patients with assigned letters later
in the alphabet than the center’s threshold letter and
allowed pre-clinic notification of potential enrollments
and sample collections to clinical and laboratory
personnel.
To maintain proportional enrollment among centers
and reduce seasonal biases, we monitored enrollment
rates at each center and adjusted the threshold letter
earlier in the alphabet for enrollment that was too rapid
and later in the alphabet for enrollment that was too
slow after the first month and quarterly thereafter begin-
ning with study month three. This enrollment speed ad-
justment strategy maintained randomization.
Table 2 Bootstrapped Power Calculationsa
Row Statistical Model Outcome Variable Biomarker, Concentration
or Activity
Percent Power α-Level Estimate of Patients Required
1 Proportional Hazards Time to first Pulmonary Exacerbation HMGB-1 90 0.01 40
2 Proportional Hazards Time to Lung Transplantation
or Death
HMGB-1 90 0.01 30
3 Linear Regression Acute FEV1% Drop with onset of
a Pulmonary Exacerbation
GMCSF 80 0.01 175
4 Linear Regression Acute FEV1% Drop with onset of
a Pulmonary Exacerbation
GMCSF 85 0.05 125
5 Linear Regression FEV1% Drop over 2 Years NE 80 0.05 32
aBased on prior published results, we sampled patients and bootstrapped statistical models of predictor biomarkers for outcome variables, setting
percent power and α-level in order to estimate the number of patients similar to prior patients needed to detect associations. See the study protocol for
more details (Additional file 5)
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We required clinical stability and a sputum sample at
enrollment. We defined clinical stability as the absence
of a pulmonary exacerbation (Table 1) [25]. Because bio-
marker values change with time following an exacerba-
tion, we collected the dates of the five exacerbations (if
any) prior to the study enrollment date to enable adjust-
ment for duration of clinical stability prior to sample
collection. Guidance and examples were presented at the
general study planning meeting and in the study proto-
col (Additional file 5, Study Protocol). Site PIs adjudi-
cated borderline cases.
Shipping controls
Prior to finalizing sputum handling protocols, we exam-
ined the effects of shipping prior to initial sample pro-
cessing on HMGB-1 measurements. We recruited 10
adult patients and collected expectorated sputum in
Utah on a single day after informed written consent. We
divided samples in two and processed half immediately
to isolate an aqueous fraction (see next section or
Additional files 6 and 7 for specific details). We added
protease inhibitor cocktail (Sigma, St. Louis, MO, USA)
and froze at − 70 °C until ready to perform HMGB-1
assay. We kept the second half of each sample on ice
and shipped to ourselves overnight at 4 °C (Fedex, Mem-
phis, TN, USA), isolated the aqueous fraction, added
protease inhibitor and froze. We measured HMGB-1
levels in both immediately-processed and shipped sam-
ples by ELISA using commercially-available antibodies
(R&D Systems, Inc., Minneapolis, MN) [25, 38]. Results
(see below) prompted incorporation of on-site sputum
processing at each center.
Sputum collection, processing and shipping
We collected sputum after expectoration. We encour-
aged collection by alternating between research and clin-
ical sample vials to minimize the disturbance of
collection for cultures, but some research samples were
collected after clinical samples [39]. We allowed sputum
induction where that method was part of usual pediatric
care. In accordance with Therapeutic Development
Network standard operating procedure [40], we allowed
one hour to collect sputum, transport from collection
point on ice and initiate laboratory processing with an
additional 1–3 h to complete processing. We further
specified that during the initial hour, collection time was
limited to 20 min, and 40 min were allowed to transport
specimens on ice and initiate laboratory processing.
Samples were collected in 50 ml conical tubes supplied
by the central study coordinators at the University of
Utah. Following collection, samples were placed on ice
and transported to the local processing laboratory.
Sputum samples were weighed, diluted 1:1 with Hanks
Buffered Saline Solution (HBSS, Sigma, St. Louis, MO)
and vortex mixed for 1 min. A sterile disposable pipette
was used to transfer 0.25 ml of the vortex mixed sample
to a 1.8 ml tube containing Streck Solution (Streck Inc.
La Vista, NE); contents were mixed using the pipette,
and the tube was sent via Fedex (Memphis, TN) to the
U of Utah for cell counts and differentials. The remain-
der of the vortex mixed sputum sample was centrifuged
for 20 min at 2800 g at 4 °C to produce a top lipid layer,
a middle aqueous layer and a bottom pellet layer. The
layers were carefully separated by transfer pipettes; all
personnel were trained to separate the layers in a way to
avoid contamination of the aqueous fraction by the other
two layers.
The lipid layer was carefully transferred to a new 1.8
ml cryovial, labeled with the participant study identifica-
tion number (ID), collection date, fraction identifier (L)
and sample number. The aqueous layer was divided in
two. The first half was diluted with HBSS (Sigma) 1:1,
vortex mixed for 10 s, aliquoted and labeled with partici-
pant study ID, date, fraction identifier (SA), sample
number and aliquot number. The second half was di-
luted with protease inhibitor cocktail (Sigma) 1:1, vortex
mixed for 10 s, aliquoted and labeled with participant
study ID, date, fraction identifier (SB), sample number
and aliquot number. The pellet was transferred to a 1.8
ml cryovial and labeled with participant study ID, date,
fraction identifier (P), sample number and aliquot num-
ber. (See Additional files 6 and 7 for illustrated instruc-
tions for sample processing.)
Fractionated samples were frozen and stored at − 70 °C
until shipping. Frozen samples were shipped on dry ice
in split batches to prevent loss of any single sample (see
Additional file 6) and immediately stored at − 70 °C in
Utah until laboratory analysis.
We collected multiple samples from participants to
address secondary study endpoints. To understand
changes in airway inflammation, we collected sputum
within 48 h of diagnosis of the first pulmonary exacerba-
tion following enrollment and a convalescent sputum
within 4–12 weeks of exacerbation onset. We encour-
aged collection of additional pulmonary exacerbation
samples, particularly if a sample was missed at the time
of first pulmonary exacerbation following enrollment. A
final sample was requested at the end of the study
whether the patient was acutely ill or stable.
A laboratory flow sheet with illustrated processing in-
structions was completed for each sample to ensure
standardized processing and enable monitoring of indi-
vidual samples (Additional file 6, Sputum Processing
Instructions and Form). Written and video sputum pro-
cessing instructions were available throughout the study
(Additional file 5 and Additional file 7, Video: Cystic
Fibrosis Biomarker Study: Sputum Collection and
Processing).
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Clinical annotation
Research coordinators collected and recorded informa-
tion simultaneously with sputum sample collections in-
cluding demographics, CFFPR identification numbers,
home address, number and dates of CF exacerbations in
the year prior to enrollment, other lung disease, smok-
ing, menstrual and pregnancy histories, treatments,
physical exam findings, spirometry results, bacterial and
alcohol and acid-fast culture results and questionnaire
results including Borg dyspnea index [41], GAD-7 anx-
iety scale [42, 43], PHQ-8 depression scale [43, 44], brief
pain index [45], selected Munich Chronotype Question-
naire [46] items (MCQ, written permission for use ob-
tained from Dr. Roenneberg) and food insecurity [47],
and dates of death or lung transplantation. Many of these
data addressed exploratory endpoints deemed interesting
and feasible and unlikely to bias enrollments by the inves-
tigators (Table 3). All data were stored using the Research
Electronic Data Capture (REDCap) system [48].
We reviewed REDCap and CF Foundation Patient
Registry data for enrollment years to identify inconsist-
encies in study data. Study coordinators from Utah per-
formed interim and end-of-study monitoring on-site to
compare entered data with electronic medical records
for every participant. Discrepancies were resolved by site
study personnel prior to analyses.
Statistical analysis
We use the R statistical system [49]. We used patient
home addresses and The National Map [50] to derive
longitude, latitude and elevation. We calculated GAD-7
and PHQ-8 total scores [42, 44], weight-for-age z-score
[9], FEV1% [30, 51], and 5-year predicted survival [9].
We used χ2, t-test, linear regression and quasi-Poisson
regression as appropriate to compare MWCFC with
CFFPR data adjusted for study site, age, sex and other
patient characteristics. We tested analyses for sensitivity
to CF-specific treatments.
Results
Shipping controls
Among 10 volunteers, 7 produced sufficient sputum for
evaluation. After overnight shipping at 4 °C, HMGB-1
levels were elevated (linear regression: coefficient = 1.15,
intercept = 5.19, p = 0.001) by factors as high as 2.8
(mean elevation factor 1.40, 95% CI = 0–2.8) compared
to paired levels from sputum processed the same day as
collection (Fig. 1).
Patients
Investigators enrolled 116 of the 154 children and 696
adults with confirmed CF in the MWCFC able to expec-
torate sputum; two patients were too young and were
excluded after enrollment (Table 4). First enrollment
was December 8, 2014; last enrollment was January 16,
2016 (Fig. 2). Five patients did not complete the sample
collection portions of the study due to lung transplant-
ation, death or other cause of loss of contact between
study center and the patient. However, all 114 patients
allowed long term follow up by providing permission to
use their specific CF Foundation Patient Registry ID
numbers. Queries specific to the study are ongoing for
end-of-study data (Table 5).
Enrollment ranged by study site from 0 to 43% and 1
to 28% of eligible children and adults, respectively. The
proportion of enrollment was unrelated to center size
for pediatric, adult or combined age groups (linear re-
gression, p > 0.1, all groups). Using linear, logistic or
quasi-Poisson regression as appropriate for the outcome
variable assessed, we evaluated seasonal effects on en-
rollment. Relative to Summer enrollment, patients en-
rolled in the Fall were 8.7 years older (p = 0.02) while
patients enrolled during the Winter had an FEV1% 15.9
percentage points higher (p = 0.004). There were no sig-
nificant relationships for sex, weight-for-age or
height-for-age [52] z-scores, number of prior year pul-
monary exacerbations, diabetes, pancreatic sufficiency,
Table 3 Data Collections for Exploratory Endpoints
Endpoints potentially related to inflammation Pertinent Clinical Data Collected
Depression, Anxiety, Pain PHQ-8 Depression Scale
GAD-7 Anxiety scale
Borg Dyspnea Index
Brief Pain Index
Environmental Factors:
Altitude, Air Pollution, Climate
Sputum Collection Date
Home Address (Latitude, Longitude, Altitude)
Microbiological Sputum Culture Results
Infection Status Sputum Culture results
Sleep and Circadian Rhythm:
Sleep Phase and Duration
Munich Chronotype Questionnaire
Menstrual Cycle Last Menstrual Period Date
Food Insecurity History of missed or potentially missed meals
GAD-7 anxiety scale
Food Availability focused questions
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5-year predicted survival [9], anxiety or depression
scores, any infection status or patient home altitude.
Despite statistically significant findings for characteris-
tics considered individually, no seasonal differences
remained significant after Bonferroni correction.
Comparison of patient characteristics with National Data
The 2014 CFFPR reports 14,394 patients able to expec-
torate sputum, 12 years of age or older. We found no
significant differences in disease characteristics, micro-
biology results or prescribed treatments compared with
MWCFC patients (Table 4).
Sputum samples
Two shipments of samples (out of approximately 30
total shipments to date for the study) arrived in Utah
partially thawed despite verified adherence to shipping
procedures and appropriate packing with dry ice at the
two originating centers. However, because we required
portions of every sample to be split at the time of
on-site processing as safeguards against shipping prob-
lems, unthawed aliquots of every sample collected were
available for laboratory analyses.
The natural log of the average cell count per milliliter
was 16.2 (SE 8.11) based on 112 of 114 enrollment
samples of sufficient volume without oral contamination
defined as ≥5 squamous epithelial cells per low power
light microscopy field on modified Wright’s stain (see
Additional file 5). The average differential of 36% neu-
trophils, 30% lymphocytes, < 1% eosinophils and 34%
other cells was based on 108 out of 112 samples. A few
samples had inadequate preservation in transport or
sparse cellularity thus less than 200 cells were counted,
but we counted 200–500 cells for the rest of the samples
in accordance with Therapeutic Development Network
standard operating procedures for samples from patients
with CF collected for inflammatory marker measure-
ments (mean 250 cells/sample, range 41–541) [40]. Total
processing time from initiation of sputum collection to
completion of processing was a mean of 54 min (SD = 1
h 38min, max time = 3 h 45min).
A total of 267 sputum samples were collected from pa-
tients. There were 116 enrollment samples, but two of
those patients were excluded because they were too
young to participate. The primary outcome for the study
is time-to-first pulmonary exacerbation, and we captured
the time-to-event data for the 92 patients who had these
events during follow up.
To address secondary outcomes, we successfully col-
lected additional data at the time of the first exacerba-
tion during study follow up for 92 of the 114 enrolled
patients and collected sputum samples for 52 of the
events. Two additional sputum samples were collected
in patients with subsequent pulmonary exacerbations
where the first exacerbation sample was missed. The
major reasons for missing first exacerbation sputum
samples were diagnosis away from the CF Care Center
and lack of ability to produce sputum within the 48 h
collection window.
Discussion
We implemented a design that focused on randomized
patient selection for a multicenter observational study of
inflammatory sputum biomarkers in CF. We achieved our
primary enrollment goal of recruiting a cohort representa-
tive of patients in the US with confirmed CF, 12 years of
age or older and able to produce sputum. Age, sex, lung
function, growth and nutrition factors, major morbidities
including pancreatic insufficiency, CF related diabetes and
airway infection prevalence and treatment frequencies
were similar between MWCFC and national patients
(Table 4). We achieved our secondary goal of minimizing
seasonal and care-center size effects on patient selection.
Randomization reduces observer-dependent selection bias
and increases believability of data collection,
generalizability of results and security of interpretation
(Additional files 1, 2, 3 and 4) [31, 32].
Our investigation of the effect of shipping on unpro-
cessed samples found a potential source of inaccuracy
Fig. 1 Shipping Effects on HMGB-1 Measurements. Overnight
shipping of refrigerated unfractionated sputum samples from seven
patients was associated with a statistically significant increase in
ELISA measurements of HMGB-1, especially for low values. Although
the values were correlated with values from samples that were
fractionated and frozen prior to shipping (see text), the large and
somewhat unpredictable sizes of differences in values and the
compressed range of values overall suggested that on-site
processing of samples would reduce measurement errors and better
enable analyses involving HMGB-1
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for HMGB-1 measurements (Additional files 3 and 4).
Overnight delay in processing was associated with large
increases in measured concentration for low values found
after same-day sputum processing. Conversely, we found
decreased values for samples processed after overnight
shipping on ice that had high measurement results from
same day processing. Together these effects appeared to
compress the range of values, potentially reducing our
ability to discriminate between patients with similar levels
of inflammation (Fig. 1). These observations coupled with
our intention of reproducing prior findings derived from
same-day processing of sputum compelled us to require
on-site processing for the current study. Shipping and
central processing of sputum might similarly affect other
potential biomarker measurements, but we did not specif-
ically address this question.
Our method of sputum sample processing repeats the
method we used to discover associations between
HMGB-1 and pulmonary exacerbations and survival
[25]. In that effort, we modified the standard operating
procedures of the Therapeutic Development Network
[40] by avoiding the use of dithiothreitol (DTT) in order
to optimize detection of some inflammatory biomarkers
[53]. Others studies of the effects of avoiding DTT and
adding protease inhibitors found that biomarker detec-
tion was improved in both cases [53–56].
Table 4 Comparison of Annualized CFFPR Data between MWCFC and other US Patients
Patient Characteristics MWCFC, n = 114 CFFPR 2014
n = 14,394
p
Enrollment Annualized for 2014
Male sex, fraction 0.46 0.46 0.48 0.79
Age, Years, mean (SD) 28 (12) 27 (12) 27 (12) 0.71
FEV1, Percent Predicted, mean (SD) 70 (22) 80 (23) 77 (27) 0.094
Height, cm, mean (SD) 167 (9.95) 167 (10.2) 166 (10) 0.39
Weight-for-age z-score, mean (SD) −0.17 (0.98) −0.20 (0.93) −0.29 (1.1) 0.34
Pulmonary exacerbations in year prior to enrollment, median (range) 1 (0–7) 1 (0–6) 1 (0–14) 0.55
Pulmonary exacerbations in year prior to enrollment, mean (SD) 1.7 (1.7) 1 (1.2) 1.1 (1.5) > 0.99
Patients with no pulmonary exacerbations, n (fraction affected) 79 (0.69) 63 (0.56) 7054 (0.52) 0.46
Diabetes, n (fraction affected) 25 (0.22) 26 (0.23) 4423 (0.31) 0.073
Pancreatic Sufficiency, n (fraction affected) 9 (0.079) 19 (0.17) 2239 (0.16) 0.84
CF related arthropathy, n (fraction affected) 8 (0.07) 10 (0.088) 697 (0.048) 0.085
5-Year Predicted Survival, median (range) 0.959 (0.094 to > 0.999) 0.973 (0.464–0.999) 0.967 (0.0949–0.999) 0.17
Home Altitude, m, mean (SD) 1305 (442) – – –
Infections Present, n (fraction affected)
Methicillin Sensitive S aureus 51 (0.45) 67 (0.59) 7937 (0.55) 0.5
Methicillin Resistant S aureus 21 (0.18) 33 (0.29) 5001 (0.35) 0.23
P aeruginosa 70 (0.61) 84 (0.74) 10,096 (0.70) 0.47
B cepacia complex 3 (0.026) 5 (0.044) 782 (0.054) 0.78
S maltophilia 7 (0.061) 26 (0.23) 2970 (0.21) 0.65
Achromobacter spp 5 (0.044) 11 (0.096) 1579 (0.11) 0.76
Candida spp 17 (0.15) 17 (0.15) 3100 (0.22) 0.11
Aspergillus 12 (0.11) 26 (0.23) 3091 (0.21) 0.82
Mycobacterium avium-intracellulare complexa 1 (0.0088) 8 (0.082) 730 (0.069) 0.74
Mycobacterium abscessusa 3 (0.027) 5 (0.052) 527 (0.05) > 0.99
Treatments in use, n (fraction affected)
Any Form of Inhaled Tobramycin 38 (0.33) 71 (0.62) 8069 (0.58) 0.38
Inhaled Aztreonam 40 (0.35) 47 (0.41) 4977 (0.36) 0.25
Oral Azithromycin 62 (0.54) 67 (0.59) 8595 (0.60) 0.91
Inhaled Hypertonic Saline 71 (0.62) 82 (0.72) 9611 (0.69) 0.54
Inhaled DNase 101 (0.89) 106 (0.93) 12,168 (0.87) 0.087
aFractions reported reflect that 97 MWCFC and 10,618 CFFPR patients had acid fast bacterial cultures performed in 2014. MWCFC patients were more likely to
undergo acid fast cultures than non-study patients (p = 0.008, χ-square test)
Liou et al. BMC Medical Research Methodology           (2019) 19:88 Page 8 of 13
Despite the care taken, our study has limitations. We
originally planned to enroll up to 175 patients (Table 2,
row 3) based on the analysis of numbers of patients
needed to replicate our prior results with GMCSF with a
high level of precision to answer our research question
(Additional files 1 and 4) [25] about the relationship be-
tween GMCSF and acute FEV1% drop with onset of a
pulmonary exacerbation, a secondary goal. Unfortu-
nately, we fell short of the planned number; however,
the actual number of patients enrolled still allows us to
address this question (Table 2, row 4) and well exceeded
the estimated numbers of adult and pediatric patients to
replicate prior results that revealed relationships be-
tween HMGB-1 and pulmonary exacerbations, our pri-
mary goal. We additionally achieved recruitment
numbers to provide sufficient power to analyze second-
ary outcomes including relationships between HMGB-1
and NE with pulmonary exacerbations, subsequent lung
function and combined lung transplant and death out-
comes (Table 2, rows 1, 2 and 5).
Because the study was non-interventional, we did not
include the final question of the PHQ-9 regarding spe-
cific plans to commit suicide, because positive answers
would have required intervention and a different regula-
tory approval pathway. Instead, we alerted clinicians to
patients with high PHQ-8 scores and requested them to
consider intervention as part of usual clinical care; this
plan was specifically approved by all site IRB’s.
We attempted to reduce bias against enrollment of pa-
tients that frequently miss clinic appointments. However,
Fig. 2 Patient Enrollment Distribution. The number of patients enrolled varied through the enrollment period of the study. Analyses
demonstrated that there were no detectable seasonal biases introduced by differences in enrollments
Table 5 Collections
Collection Type Enrollment First Pulmonary
Exacerbation Onseta
First Pulmonary
Exacerbation Convalescence
Additional
Exacerbation
End of Study Follow Upb
Clinical Data 114 92 36 10 72
Samples 114c 52 29 8 62
aFollow up varied and sometimes exceeded one year to the first exacerbation. Among enrolled patients, 81% had an exacerbation during the study. However, the
observed percentage of patients with exacerbations within 1 year was lower, 47%, and was similar to the 44% reported in annualized 2014 CFFPR data for this
cohort of patients (Table 4)
bQueries for data from the end-of-study are ongoing at the time of submission
c114 samples were collected, however, only 112 were sufficient in size to allow laboratory analyses
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the nature of clinic non-adherence likely still reduced
enrollment of these patients and may have reduced our
ability to collect subsequent samples and data for our
secondary study goals.
We successfully collected samples for only 52 out of
92 patients who suffered pulmonary exacerbations dur-
ing study follow up. The high degree of missingness sug-
gests that there may be hidden biases in studies of
pulmonary exacerbation. Because most samples were
missed due to diagnosis at non-participating care cen-
ters, distance-to-center or other reasons that impede
care at an accredited CF Care Center may be previously
unrecognized sources of bias in studies of pulmonary ex-
acerbation. Further analyses of the current data and add-
itional future studies designed to collect sputum from
outlying care centers may help to understand the nature,
size and effect of such bias.
Our study did not enroll patients with the same clinical
status as in prior studies [5, 24, 25, 27]. Prior patients were
non-randomly selected often after or during a pulmonary
exacerbation. We reasoned that predictions from bio-
markers measured during clinical stability would be most
generally useful, thus our current study patients may be
less ill as a group than previously reported patients.
Conclusions
We designed and implemented an observational study of
stable patients with CF able to produce sputum to iden-
tify inflammatory biomarkers predictive of clinically im-
portant outcomes. Our design and enrollment efforts
recruited a well characterized cohort from the MWCFC
region similar to sputum-producing patients throughout
the US that participate in the CFFPR. This cohort pro-
vides a believable and generalizable foundation in suffi-
cient numbers for clinical interpretation of upcoming
analyses of biochemical marker measurements from the
carefully collected and annotated sputum samples.
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